Stories from independent and tier-1 publishers. Filter by vertical, search by topic, listen anywhere — your audio sidekick handles the rest.
Two chipmakers are the new apples of Apple’s eye.
It doesn’t seem that long ago that we were jostling for Covid-19 vaccines, lining up to get Pfizer’s name (or Moderna’s) scrawled onto cards we kept in our wallets to get into a bar.
Thankfully, we didn’t take out that event contract on the launch of the first prediction-market ETFs this week.